Our goal is to provide the highest level of care to all of our patients, and that includes offering novel treatments before they are widely available. If you are a cancer patient, you may be eligible for one of our current clinical trials.

Anal Cancer

  • Stage IV
  • A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Bile Duct Cancer

  • Stage III/IV
  • A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel vs Paclitaxel Alone in Adult Pts with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received 1 Prior Systemic Chemotherapy Regimen CTX-009-002
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Bladder Cancer

  • Stage II or Stage III
  • A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • Afatinib (BIBW 2992) in Advanced Refractory Urothelial Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 

Breast Cancer

  • Stage I-IIIC
  • The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage II-III
  • xOptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage I-III
  • Optimizing Endocrine Therapy through Motivational Interviewing and Text Interventions
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IIIA
  • A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage T2 - IIIC 
  • Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IB-IIIC
  • A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage — Stage 0-pTis
  • Cluster Randomized Controlled Trial Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ–Making Informed Choices on Incorporating Chemoprevention into Care MiCHOICE
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV or Unresectable Stage III
  • A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (nab-paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • Phase II Study of Pembrolizumab and Mifepristone in Patients with Advanced HER2-Negative Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • The GLORIA Study: A Phase III, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI 822)/OBI 821 in the Adjuvant Treatment of Patients with High Risk Early Stage Globo H-Positive Triple Negative Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage IV
  • Randomized Phase II Study of Sacituzumab Govitecan with or without Pembrolizumab in Hormone Receptor-Positive (HR+) / HER2- Metastatic Breast Cancer (MBC)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • Title Randomized Phase II Study of Sacituzumab Govitecan with or without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage II or Stage III
  • A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Phase 1 Pilot Study with Dose Expansion of Chemotherapy in Combination with CD40 Agonist and Flt3 Ligand in Metastatic Triple Negative Breast Cancer (SCCC-03121)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage I-III
  • A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Colon/Rectal Cancer

  • Stage II - III
  • Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II To Phase III Study
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IIA
  • Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage II or Stage III
  • Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • A Phase 1b/2 Study of VS-6766 and Cetuximab in Patients with Advanced KRAS Mutated Colorectal Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Gastric Cancer (Stomach Cancer)

  • Randomized Phase III Trial of MFolfirinox +/- Nivolumab vs. Folfox +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IB - IIIC
  • PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (ZWI-ZW25-201)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Gynecologic Cancer

  • Relapsed / Refractory
  • Randomized Phase II/III Study of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage III - IV
  • A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer (AFT-50 - Endomap)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Head and Neck Cancer

  • A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage - varies
  • Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • TARGET HPV: A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination with Neoadjuvant Chemotherapy followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer.
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Phase II Study of Pembrolizumab in Combination with Circulating Tumor DNA Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY trial (Squamous cell carcInoma of head and NEck Response-Guided therapY)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Kidney Cancer

  • Stage IV
  • Nivolumab and Ipilimumab followed by Nivolumab versus VEGF TKI Cabozantinib with Nivolumab: Phase III Trial in Metastatic Untreated Renal Cell Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Leukemia

  • Any Newly Diagnosed
  • Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage I - IV
  • Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 

Lung Cancer

  • Stage IIIB-IV
  • Study Title A Phase 1B Study of Venetoclax in Combination with Pembrolizumab in Subjects with Previously Untreated Non-Small Cell Lung Cancer Whose Tumors have High PD-L1 Expression
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IIIB-C or Stage IV
  • A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage IV
  • Randomized Phase 3 Study of Combination AZD9291 (Osimertinib) and Bevacizumab versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

  • Stage IV
  • Master Protocol to Evaluate Biomarker-Drive Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV or recurrent disease
  • Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP Sub-Study)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage I-II
  • Phase III Randomized Placebo-Controlled Double-Blind Multi-Center International Study of Durvalumab with Stereotactic Body Radiation Therapy for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Phase II Trial of Durvalumab (MEDI4736) and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer (DARES)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Pts with Advanced or Metastatic Non-Small Cell Lung Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 

Lymphoma

  • Stage I - IV
  • Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage varies 
  • Phase II Study of Pembrolizumab in Combination with R-CHOP for Patients with Untreated, High-Risk, Non-Germinal Center-Derived DLBCL
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Phase II Study of Pembrolizumab for PD-L1 Gene-Altered, Relapsed/Refractory DLBCL
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Phase I/II Study of Acalabrutinib, Venetoclax and Obinutuzimab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Myelodysplastic Syndrome (MDS)

  • Stage – not applicable
  • Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Multiple Myeloma

  • High-Risk SMM
  • Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Open-label, Single-arm, Phase 2 Study of Initial Treatment with Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Phase II Study of Belantamab Mafodotin in Combination with Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients with Relapsed Multiple Myeloma
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Neuroendocrine Tumors

  • Stage IV
  • A Randomized Phase II/III Trial of First Line Platinum/ Etoposide with or without Atezolizumab in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Pancreas Cancer

  • Creon® (pancrelipase) therapy for subjects with exocrine pancreatic insufficiency (EPI) due to pancreatic cancer: A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects
  • If you are eligible and would like to participate, please contact the research staff at 708-915-4673 (HOPE) or send an email to clinicaltrials@ingalls.org.
  • Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Prostate Cancer

  • Stage IV
  • A Phase II Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A-DREAM
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Phase II Multi-Dose Multi-Arm Parallel Assignment Study to Evaluate Safety, Tolerability and Preliminary Efficacy of XmAb®20717 Alone or in Combination with Chemo or Targeted Therapies in Selected Patients with Metastatic Castration-Resistant Prostate Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Phase Ib Study of Extending Relugolix Dosing Intervals Through Addition of the CYP3A4 and P-gp Inhibitor Itraconazole or Ritonavir in Prostate Cancer Patients
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients with High-Risk Localized Prostate Cancer
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Solid Tumors and Multiple Disease Sites

  • Locally Advanced / Stage IV
  • Phase 1b Dose‑Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors 
  • If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Recurrent / Metastatic Stage IV
  • Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  •  Any Stage
  • A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • Stage IV
  • A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage III or Stage IV
  • An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A First-In-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
  • A Phase 1 Study of ZN-c3 as a Single Agent in Subjects with Solid Tumors
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Stage IV
  • ART0380C004. A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients with Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Supportive Care

  • Advanced Stage
  • Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 

Biobanking

  • Protocol for Lymphoma Program Biobank
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.
 
  • Any Stage 
  • Genomic Analysis to Identify Correlates of the Inflamed Tumor-Phenotype in Patients with Advanced Malignancies Receiving Immunotherapy
  • If you would like to learn more about this study, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.